These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15293848)

  • 1. Clinical characteristics of vesnarinone.
    Feldman AM
    Drug Saf; 2004; 27 Suppl 1():1-9. PubMed ID: 15293848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.
    Feldman AM; Bristow MR; Parmley WW; Carson PE; Pepine CJ; Gilbert EM; Strobeck JE; Hendrix GH; Powers ER; Bain RP
    N Engl J Med; 1993 Jul; 329(3):149-55. PubMed ID: 8515787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
    Cohn JN; Goldstein SO; Greenberg BH; Lorell BH; Bourge RC; Jaski BE; Gottlieb SO; McGrew F; DeMets DL; White BG
    N Engl J Med; 1998 Dec; 339(25):1810-6. PubMed ID: 9854116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vesnarinone: a new inotropic agent for treating congestive heart failure.
    Cavusoglu E; Frishman WH; Klapholz M
    J Card Fail; 1995 Jun; 1(3):249-57. PubMed ID: 9420657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
    Bertolet BD
    Drug Saf; 2004; 27 Suppl 1():11-8. PubMed ID: 15293849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of vesnarinone on cardiac function in patients with severe congestive heart failure.
    Scherrer-Crosbie M; Cocca-Spofford D; DiSalvo TG; Semigran MJ; Dec GW; Picard MH
    Am Heart J; 1998 Nov; 136(5):769-77. PubMed ID: 9812070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy.
    Kass DA; Van Anden E; Becker LC; Kasper EK; White WB; Feldman AM
    Am J Cardiol; 1996 Sep; 78(6):652-6. PubMed ID: 8831399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. Vest Withdrawal Substudy Group.
    Soran O; Young JD; Holubkov R; Loftus S; Bourge R; Carson P; Jaski B; White BG; Feldman AM
    J Card Fail; 1999 Sep; 5(3):195-200; discussion 201-2. PubMed ID: 10496192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure.
    Matsumori A; Shioi T; Yamada T; Matsui S; Sasayama S
    Circulation; 1994 Mar; 89(3):955-8. PubMed ID: 8124835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesnarinone: a potential cytokine inhibitor.
    Sasayama S; Matsumori A
    J Card Fail; 1996 Sep; 2(3):251-8. PubMed ID: 8891863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial.
    Deswal A; Petersen NJ; Feldman AM; White BG; Mann DL
    Chest; 2001 Aug; 120(2):453-9. PubMed ID: 11502643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimising outcomes in end-stage heart failure: differences in therapeutic responses between diverse ethnic groups.
    Sasayama S
    Drug Saf; 2004; 27 Suppl 1():19-24. PubMed ID: 15293850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of Chinese-made vesnarinone on experimental heart failure of dog].
    Du J; Yang Z
    Hua Xi Yi Ke Da Xue Xue Bao; 1992 Jun; 23(2):178-80. PubMed ID: 1452153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Trends in pharmacological treatment of congestive heart failure].
    Halawa B
    Pol Merkur Lekarski; 1999 Mar; 6(33):152-6. PubMed ID: 10365602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New knowledge on the subject of therapy in cardiac decompensation in the light of large trials].
    Camerini F; Perkan A; Sinagra G; Di Lenarda A; Pinamonti B; Zecchin M
    Ann Ital Med Int; 1994 Oct; 9 Suppl():68S-77S. PubMed ID: 7857761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The best of times, the worst of times: the wealth and poverty of heart failure pharmacotherapies: is there a role for vesnarinone?
    Young JB
    Drug Saf; 2004; 27 Suppl 1():3 p following table of contents. PubMed ID: 15293847
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety.
    Furusawa S; Ohashi Y; Asanoi H
    J Clin Pharmacol; 1996 May; 36(5):477-81. PubMed ID: 8739027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies.
    Reis SE; Holubkov R; Young JB; White BG; Cohn JN; Feldman AM
    J Am Coll Cardiol; 2000 Aug; 36(2):529-33. PubMed ID: 10933368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carvedilol and vesnarinone: new antiarrhythmic approach in heart failure therapy.
    Cheng JH; Kamiya K; Kodama I
    Acta Pharmacol Sin; 2001 Mar; 22(3):193-200. PubMed ID: 11742564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.